Jonah Comstock is the Editor in Chief at pharmaphorum. He specializes in health tech journalism, focusing on themes such as healthcare technology, medicine, and alternative medicine, with particular interests in oncology, digital health, and psychedelic research. Jonah's insights and expertise are featured prominently in pharmaphorum.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .
The FDA has officially granted approval for Regeron's garetosmab-grts, to be sold under the brand name Pasatru.
Anthropic's Claude Science performed impressively in a protein design exercise, designing binders against 14 out of 15 targets and improving, in many cases, on the results of design competitions tackling those same targets.
Eric Schadt, a serial entrepreneur and expert in computational biology, is leaving his post as Chief Scientist at Pathos AI to start a new, stealthy venture -- and signing on as Pfizer's first AI Scholar in the process.
Johnson & Johnson has secured another approval for its multiple myeloma drug Tecvayli (teclistamab), with the European Commission granting approval
The appointments brought together veterans from across the pharmaceutical industry, venture capital, healthcare technology, and academia.
The European Commission has granted marketing authorisation to Gilead for Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) for
A year after officially launching its AI agency offering , EVERSANA is expanding the platform's capabilities and announcing a major pharma
The US FDA announced two De Novo marketing authorisations for novel medical devices this week: A continuous glucose monitor that also monitors
Revolution Medicines' Rasonque (daraxonrasib), the RAS inhibitor that received a standing ovation at ASCO for its doubling of overall survival in
Employers in the United States are facing rising healthcare costs for next year, and drug prices are a major driver of that increase, according to a new survey released today by the Business Group on Health.
